A 42-year-old woman from Mumbai with MDR-TB (confirmed by culture + DST: resistant to INH and RIF) on second-line therapy for 6 months shows clinical deterioration and persistent positive sputum culture. Resistance to fluoroquinolone is suspected. Which investigation is most appropriate to detect resistance to second-line drugs and confirm XDR-TB status?

Explanation

## Investigation of Choice for Detecting XDR-TB ### Definition and Diagnostic Challenge **Key Point:** XDR-TB is defined as MDR-TB with additional resistance to at least one fluoroquinolone AND at least one injectable agent (amikacin, kanamycin, or capreomycin). Rapid detection of second-line drug resistance is critical for timely treatment modification. ### Why Rapid Molecular LPA is Most Appropriate 1. **Speed:** Results in 1–2 days (vs. 2–8 weeks for culture + DST) 2. **Targets key resistance genes:** - *gyrA* and *gyrB* mutations → fluoroquinolone resistance - *rrs* and *eis* mutations → injectable agent resistance 3. **WHO-endorsed** for rapid detection of second-line drug resistance 4. **Suitable for smear-positive and smear-negative samples** 5. **High sensitivity and specificity** for XDR-TB confirmation ### Comparison of Investigations for Second-Line Drug Resistance | Investigation | Speed | Detects FQ Resistance | Detects Injectable Resistance | Practical Utility | |---|---|---|---|---| | **Culture + DST (LJ medium)** | 2–8 weeks | Yes | Yes | Gold standard but slow; not practical for urgent clinical decisions | | **Rapid Molecular LPA** | 1–2 days | Yes (*gyrA*, *gyrB*) | Yes (*rrs*, *eis*) | **Best for rapid XDR-TB confirmation and treatment change** | | **Sputum smear + GeneXpert** | ≤2 hours | No | No | Detects RIF resistance only; useless for second-line resistance | | **HPLC** | Hours | No | No | Not a diagnostic tool for TB drug resistance | ### Clinical Context: Why LPA Now? **Clinical Pearl:** A patient on second-line therapy with clinical deterioration and persistent positive culture likely has XDR-TB. Waiting 2–8 weeks for culture + DST results risks disease progression and death. Rapid molecular LPA allows same-week confirmation and immediate switch to third-line agents (bedaquiline, linezolid, moxifloxacin). **High-Yield:** Line probe assay (LPA) is the WHO-recommended rapid test for detecting second-line drug resistance and confirming XDR-TB status. It should be performed on all MDR-TB cases with treatment failure or slow response. **Mnemonic:** **LPA = Line Probe Assay** — a rapid PCR-based method that detects mutations in genes encoding drug-resistance phenotypes (FQ: *gyrA*/*gyrB*; injectables: *rrs*/*eis*). ### Algorithm for XDR-TB Detection ```mermaid flowchart TD A[MDR-TB confirmed on first-line DST]:::outcome A --> B{Clinical deterioration or<br/>treatment failure?}:::decision B -->|Yes| C[Perform rapid molecular LPA<br/>for second-line drug resistance]:::action B -->|No| D[Continue second-line therapy<br/>with monitoring]:::action C --> E{LPA results:<br/>FQ + injectable<br/>resistance?}:::decision E -->|Yes| F[XDR-TB confirmed]:::outcome E -->|No| G[MDR-TB without XDR]:::outcome F --> H[Initiate third-line regimen<br/>bedaquiline + linezolid + moxifloxacin]:::action G --> I[Optimize second-line therapy]:::action ``` **Tip:** Do not wait for culture + DST results in a clinically deteriorating MDR-TB patient. Rapid LPA is the investigation of choice for urgent XDR-TB confirmation.